Literature DB >> 34346032

Emerging roles of circUBAP2 targeting miR-370-3p in proliferation, apoptosis, and invasion of papillary thyroid cancer cells.

Hui Xiong1,2, Jinsong Yu2,3, Guangwei Jia1, Yang Su1, Jianliang Zhang1, Qiu Xu1, Xiaoxiong Sun4.   

Abstract

Circular RNAs (circRNAs) have been documented to be aberrantly expressed in many types of malignancies and involved in cancer progression. However, their role in thyroid cancer (TC) remains largely unknown. Our study aimed to explore the role and mechanism of circUBAP2 in TC. The differentially expressed circRNAs in TC tissues were identified using GSE18105 from gene expression omnibus (GEO) database. CircUBAP2 and miR-370-3p expression was analyzed using qRT-PCR. The stability of circUBAP2 was confirmed by actinomycin D and RNase R. The subcellular localization of circUBAP2 was detected using cell fractionation assay. Cell proliferation, apoptosis, and invasion were evaluated using MTT, flow cytometry analysis, and Transwell invasion assay, respectively. The interaction between circUBAP2 and miR-370-3p was predicted using bioinformatics analysis and validated by luciferase reporter assay, RNA pull-down assay, and RNA immunoprecipitation. CircUBAP2 was upregulated and miR-370-3p was downregulated in TC tissues and cells. CircUBAP2 was highly stable, resistant to RNase R digestion, and predominantly localized in the cytoplasm. CircUBAP2 knockdown inhibited cell proliferation and invasion and triggered apoptosis in TC cells. Bioinformatics analysis showed that circUBAP2 contained putative binding sites of miR-370-3p. CircUBAP2 acted as a sponge to inhibit miR-370-3p expression. Mechanistically, miR-370-3p inhibition abolished the effects of circUBAP2 on proliferation, apoptosis, and invasion in TC cells. Taken together, CircUBAP2 knockdown impeded the proliferation and invasion and induced apoptosis in TC cells via sponging miR-370-3p.
© 2021. Japan Human Cell Society.

Entities:  

Keywords:  Apoptosis; CircUBAP2; Invasion; Proliferation; Thyroid cancer; miR-370-3p

Mesh:

Substances:

Year:  2021        PMID: 34346032     DOI: 10.1007/s13577-021-00585-1

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  45 in total

1.  Role of BRAF and RAS Mutations in Extrathyroidal Extension in Papillary Thyroid Cancer.

Authors:  Ji Yeon Park; Jin Wook Yi; Chan Hee Park; Younggyun Lim; Kye Hwa Lee; Kyu Eun Lee; Ju Han Kim
Journal:  Cancer Genomics Proteomics       Date:  2016 Mar-Apr       Impact factor: 4.069

Review 2.  Thyroid cancer.

Authors:  Maria E Cabanillas; David G McFadden; Cosimo Durante
Journal:  Lancet       Date:  2016-05-27       Impact factor: 79.321

Review 3.  The changing incidence of thyroid cancer.

Authors:  Cari M Kitahara; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2016-07-15       Impact factor: 43.330

4.  Cervical soft tissue recurrence of differentiated thyroid carcinoma after thyroidectomy indicates a poor prognosis.

Authors:  Luying Gao; Yuxin Jiang; Zhiyong Liang; Lei Zhang; Xinxin Mao; Xiao Yang; Ying Wang; Jingzhu Xu; Ruyu Liu; Shenling Zhu; Ruina Zhao; Xingjian Lai; Xiaoyan Zhang; Bo Zhang
Journal:  Int J Surg       Date:  2017-09-14       Impact factor: 6.071

Review 5.  Anaplastic thyroid carcinoma: review of treatment protocols.

Authors:  Vera Tiedje; Martin Stuschke; Frank Weber; Henning Dralle; Laura Moss; Dagmar Führer
Journal:  Endocr Relat Cancer       Date:  2018-01-02       Impact factor: 5.678

6.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Authors:  Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

7.  Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?

Authors:  Eyun Song; Min Ji Jeon; Hye-Seon Oh; Minkyu Han; Yu-Mi Lee; Tae Yong Kim; Ki-Wook Chung; Won Bae Kim; Young Kee Shong; Dong Eun Song; Won Gu Kim
Journal:  Eur J Endocrinol       Date:  2018-06-06       Impact factor: 6.664

Review 8.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

9.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

Review 10.  MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma.

Authors:  Agnieszka Zembska; Aleksandra Jawiarczyk-Przybyłowska; Beata Wojtczak; Marek Bolanowski
Journal:  Anticancer Res       Date:  2019-01       Impact factor: 2.480

View more
  4 in total

1.  Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.

Authors:  Leiming Wang; Xi Yang; Fei Zhou; Xuesi Sun; Shulin Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 2.  Function and Clinical Significance of Circular RNAs in Thyroid Cancer.

Authors:  Xuelin Yao; Qiu Zhang
Journal:  Front Mol Biosci       Date:  2022-07-22

Review 3.  A Review and In Silico Analysis of Tissue and Exosomal Circular RNAs: Opportunities and Challenges in Thyroid Cancer.

Authors:  Eman A Toraih; Mohammad H Hussein; Manal S Fawzy; Emad Kandil
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

4.  CircPTPRM accelerates malignancy of papillary thyroid cancer via miR-885-5p/DNMT3A axis.

Authors:  Daping Chen; Xijiao Jiang; Huizhou Luo; Qingquan Hua; Farong Zhang
Journal:  J Clin Lab Anal       Date:  2022-09-13       Impact factor: 3.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.